지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Background: Immunotherapy has become established as a new cancer treatment that enhances patients’ immune systems’ ability to fight cancer. Immune checkpoint inhibitors (ICI) have demonstrated remarkable benefits in the treatment of a range of cancer types. The increasing use of immune-based therapies has exposed a discrete group of immune-related adverse effects. Effective recognition and treatment of ICI-induced toxicities have emerged as essential goals of ICI management.
Current Concepts: Gastrointestinal (GI) and hepatic adverse effects of ICI treatment are relatively common.
Immune-related GI or hepatic toxicities occur in approximately 30% of patients. The incidence of grade 3 or 4 adverse effects ranges from 0.5% to 2%. The management strategy for immune-related adverse effects depends on their severity. In general, ICI treatment can be continued with close monitoring for mild (grade 1) GI/hepatic toxicities. ICI treatment should be interrupted for most grade 2 to 4 toxicities, and systemic steroid administration is recommended. If steroids are ineffective, immunosuppressive agents such as infliximab may be used. When symptoms and laboratory values revert to grade 1 or less, ICI treatment may be resumed with caution. Grade 4 toxicities warrant permanent discontinuation of ICI treatment.
Discussion and Conclusion: Most immune-related GI and hepatic adverse effects are mild to moderate in severity and can be managed with supportive care, steroid therapy, and other immunomodulatory agents.
Management of ICI-related toxicities in the GI and hepatic systems requires close collaboration between the patient, the treating oncologist, and other specialists.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
면역항암치료의 부작용 관리: 호흡계와 신경계를 중심으로
대한의사협회지
2023 .02
-
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Immune Network
2020 .02
-
Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management
Korean Circulation Journal
2021 .01
-
마이크로바이옴과 암 면역 치료
대한내과학회지
2021 .08
-
면역관문억제제 투여 환자의 간기능 이상반응 분석
병원약사회지
2022 .11
-
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Immune Network
2020 .02
-
BNT162b2 접종과 면역관문억제제 치료 이후 발생한 이상 반응 1예
대한내과학회지
2023 .04
-
Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report
Journal of Yeungnam Medical Science
2021 .10
-
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
Immune Network
2022 .02
-
Immunotherapy for prostate cancer: Requirements for a successful regime transfer
Investigative and Clinical Urology
2022 .01
-
Impact of pretreatment body mass index on clinical outcomes in patients with metastatic renal cell carcinoma receiving first-line immune checkpoint inhibitor-based therapy: A systematic review and meta-analysis
Investigative and Clinical Urology
2024 .09
-
Multidisciplinary insight for managing immune checkpoint inhibitor-related myocarditis: a case report
Medical Biological Science and Engineering
2024 .01
-
Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
Immune Network
2020 .02
-
Complications of immunotherapy in advanced hepatocellular carcinoma
Journal of Liver Cancer
2024 .03
-
Leukocytoclastic Vasculitis-Induced Lower Leg Ulceration in the Course of Immune Checkpoint Inhibitor Therapy for Advanced Malignant Melanoma: A Case Report
Journal of Wound Management and Research
2024 .06
-
Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
Clinical Transplantation and Research
2022 .06
-
표적항암치료의 부작용 관리
대한의사협회지
2023 .02
-
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Immune Network
2020 .02
-
Recent Progress in Immunotherapy for Gastric Cancer
Journal of Gastric Cancer
2023 .01
-
Proper management of adverse effect in immune therapy
대한임상종양학회 학술대회지
2022 .02
이 논문의 저자 정보
최근 본 자료
댓글(0)
0